BPGAM
ESPR icon

BTG Pactual Global Asset Management’s Esperion Therapeutics ESPR Stock Holding History

BTG Pactual Global Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,719
Closed -$342K – 71
2018
Q2 		$342K Buy
8,719
+1,465
+20% +$74K 0.1% 55
2018
Q1 		$525K Buy
+7,254
New +$533K 0.14% 54

Other funds holding ESPR

BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BTG Pactual Global Asset Management's ESPR Position: Q3 2018 in Review

BTG Pactual Global Asset Management sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 8,719 shares — an estimated $342K sold.

BTG Pactual Global Asset Management first reported a position in ESPR in Q1 2018 and held it in 2 quarters. The position peaked at $525K in Q1 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • BTG Pactual Global Asset Management reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • BTG Pactual Global Asset Management sold 8,719 Esperion Therapeutics shares in Q3 2018, an estimated $342K.
  • BTG Pactual Global Asset Management first reported a position in Esperion Therapeutics in Q1 2018 and held it in 2 quarters.
  • BTG Pactual Global Asset Management's Esperion Therapeutics position peaked at $525K in Q1 2018.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on BTG Pactual Global Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.